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Conclusion. A course of immunosuppressive treatment ad-Conservative versus immunosuppressive treatment of patients
ministered early at the onset of renal function decline induceswith idiopathic membranous nephropathy.
a favorable effect in most of patients with MGN and deteriorat-Background. Treatment of idiopathic membranous glomer-
ing renal function. Untreated patients progressed without ex-ulonephritis (MGN) is a controversial issue. Whereas some
ception toward advanced renal failure.authors recommend early immunosuppressive treatment of all
patients with nephrotic syndrome, others do not support ag-
gressive therapies, based on the spontaneous long-term favor-
able outcome of most patients. However, 20 to 50% of un- Treatment of membranous glomerulonephritis (MGN)treated patients develop progressive renal insufficiency.
remains a very controversial issue [1]. Whereas some au-Methods. All of the patients with biopsy-proven MGN who
thors recommend a conservative approach, given thedeveloped renal insufficiency at our Hospital during the period
of 1975 to 2000 were studied. Selected patients (N  39) were high incidence of spontaneous remissions and the long-
separated into two groups according to the two different thera- term good prognosis of most of the patients [2], other
peutic policies followed at our department: a conservative ap- authorities administer a course of immunosuppressiveproach during the first period, 1975 to 1989 (group I, N  20),
drugs to all the patients with nephrotic syndrome, sinceand a course of immunosuppressive therapy (oral prednisone
several prospective and controlled studies have demon-for six months and concurrent oral chlorambucil, 0.15 mg/kg/
day, during the first 14 weeks) during the second period, 1990 strated the superiority of this regimen compared with
to 2000 (group II, N  19). the conservative approaches [3–5]. This latter aggressive
Results. There were no significant differences between both management of MGN has been criticized because many
groups at the time of renal biopsy, nor at the onset of renal func-
patients who probably would evolve into spontaneoustion decline. All group I patients showed a progressive renal
remissions are exposed to the risks of immunosuppres-insufficiency; at the end of the follow-up 13 patients (65%) were
on chronic dialysis, 2 (10%) showed advanced renal failure, and sive therapies. On the other hand, the conservative ap-
5 (25%) had died. In contrast, most of group II patients showed proach without the attempt of immunosuppressive treat-
an improvement or stabilization of serum creatinine (SCr; 2.3 ment would leave a considerable percentage of patients
0.9 mg/dL at onset of treatment, 2  1.5 mg/dL at the end of
(ranging from 20% to more than 50% in some studies)follow-up) together with decreased proteinuria (11.2  3.3 vs.
with a progressive derangement of renal function [6–11].5.2  6.7 g/24 h). At the end of the follow-up 58% of group II
To resolve this contradiction, several authors havepatients had a SCr value 1.5 mg/dL and 36% showed a com-
plete or partial remission, whereas no patient in group I showed proposed a more flexible approach, selecting only those
remission. After four years of follow-up the probability of patients at highest risk for progressive disease for immu-
renal survival without dialysis was 55% in group I and 90% nosuppressive therapies. Several clinical and biochemi-in group II (P 0.001), and after seven years the renal survival
cal parameters that would define a bad prognosis (menwas 20% and 90%, respectively (P  0.001). Side effects of
over the age of 50 years, sustained massive proteinuriaimmunosuppressive treatment were uncommon but severe, as
two patients suffered Pneumocystis carinii pneumonia. values, elevation of serum creatinine) have been pro-
posed to establish such a selection [12–16]. Among these,
the presence of deteriorated renal function, at presenta-
1 See Editorial by Cattran, p. 349. tion or throughout the evolution of the disease, appears
to be the strongest clinical predictor of progression toKey words: nephrotic syndrome, immunosuppression, progressive re-
nal disease, kidney deterioration, proteinuria, renal failure. advanced renal failure, since the spontaneous recovery
of normal renal function (once the functional factors inReceived for publication May 14, 2001
the setting of nephrotic syndrome and diuretic therapyand in revised form August 1, 2001
Accepted for publication August 31, 2001 are excluded) is the exception in MGN.
Some studies have reported a beneficial effect of im- 2002 by the International Society of Nephrology
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munosuppressive treatments in MGN with deteriorating even in those patients showing progressive renal insuffi-
ciency. Salt restriction, diuretic therapy, lipid-loweringrenal function [17–25]. The present study reports our
experience with MGN patients who develop progressive agents and antihypertensive drugs (including ACE inhib-
itors as antiproteinuric agents) were the basis of treat-renal failure. Until 1990 we maintained a conservative
approach, avoiding the use of steroids or cytotoxic drugs ment. In those patients showing a decline in renal func-
tion, no specific changes in the treatment were adopted,even in patients showing a progressive decline in renal
function. Thus, during the period of 1975 to 1989, 67 except the reduction or withdrawal of drugs (mainly di-
uretics and ACE inhibitors) that could play a role inpatients with idiopathic MGN were studied, 20 of whom
(29.8%) showed progressive renal insufficiency. Since renal function derangement.
1990, we have decided to administer a course of immu-
Second period (1990 to 2000)nosuppressive treatment (steroids plus chlorambucil) to
all MGN patients presented with impaired renal func- A retrospective analysis of our patients with MGN
performed in 1989 showed a uniform evolution towardtion. Thus, during the period of 1990 to 2000, 19 patients
out of a total of 55 (34.5%) idiopathic MGN received advanced renal failure in every patient with a decline
in renal function. Therefore, we decided to change ourthis treatment because of the appearance of renal insuf-
ficiency. The outcomes of both cohorts are compared: policy, administering a course of immunosuppressive
treatment to every new patient with idiopathic MGN ingroup I was managed conservatively (period 1975 to
1989) and group II was treated with immunosuppressive whom renal insufficiency of recent onset (defined by
the above criteria) was detected. Immunosuppressivedrugs (period 1990 to 2000).
treatment consisted of oral prednisone for six months
starting with 1 mg/kg/day for the first month, 0.5 mg/kg/
METHODS
day for the second month and 0.5 mg/kg/every other day
All biopsy-proven patients with idiopathic MGN who from third to sixth months, accompanied by simultane-
developed progressive renal insufficiency assessed at our ous oral chlorambucil (0.15 mg/kg/day) during the first
Hospital in the period of 1975 to 2000 were included 14 weeks (31⁄2 months). Prophylactic treatment with tri-
in this study. The medical records of all the patients methoprim-sulfamethoxazole (3 times/week for 6 months
diagnosed as having MGN were reviewed in order to since the beginning of the prednisone/chlorambucil treat-
identify those showing renal insufficiency. Excluded ment) was instituted in 1994, after the appearance of
from the study were those patients with systemic lupus Pneumocystis carinii pneumonia in two patients.
erythematosus or any other systemic disease, diabetes Treatment of patients with normal renal function was
mellitus, chronic infectious diseases (including infections the same as before, that is, salt restriction, diuretics, lipid-
by hepatitis B and C viruses and HIV), drug-induced lowering drugs, antihypertensive agents including the pref-
MGN, hematologic diseases, and every patient in whom erential use of ACE inhibitors because of their antipro-
a diagnosis of secondary MGN has been established dur- teinuric effect. Again, in every patient showing a renal
ing the study. function decline, the reversible functional causes (such
Renal insufficiency was defined as a serum creatinine as diuretics and ACE inhibitors) were carefully ruled out
(SCr) 1.5 mg/dL together with a creatinine clearance before the patient initiated immunosuppressive therapy.
(CCr) 60 mL/m, in at least three consecutive determi- All of the included patients were biopsied at our Hos-
nations. Renal insufficiency was progressive in all the pital and thereafter followed at regular intervals (every
included patients. Before considering progressive renal in- 1 to 3 months) at our outpatient clinic. The following
sufficiency attributable to the glomerular disorder, func- data at the time of renal biopsy and at every visit were
tional factors such as overzealous diuretic therapy, and obtained from medical records and analyzed for the pres-
angiotensin-converting enzyme (ACE) inhibitors and non- ent study: age, gender, interval of time between the per-
steroidal anti-inflammatory drugs (NSAIDs) were care- formance of renal biopsy and the appearance of renal
fully ruled out. When clinically suspected (flank pain, insufficiency, blood pressure, SCr, CCr, and 24 hour pro-
hematuria, very sudden onset of renal insufficiency, pul- teinuria. The duration of follow-up between the appear-
monary emboli, suggestive radiological findings) renal ance of renal insufficiency until the last visit, death or the
vein thrombosis was always ruled out. onset of chronic dialysis was calculated in every case. All
renal biopsies were processed by light microscopy, im-
munofluorescence and electron microscopy. The stage ofTHERAPEUTIC APPROACHES
MGN (stages I to IV) was reviewed in every case. The
First period (1975 to 1989) severity of interstitial fibrosis was graded semiquantita-
During these years a conservative attitude towards the tively on a scale of 0 to 4, with 0  none and 4  severe.
treatment of patients with idiopathic MGN was main- Complete remission was defined as a proteinuria
0.5 g/24 h with normal serum albumin and normal renaltained, and immunosuppressive treatments were avoided
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Table 1. Clinical features of group I patients (conservativefunction. Partial remission was defined as a proteinuria
treatment) and group II (immunosuppressive treatment)
between 0.5 and 2.5 g/24 h, or a decrease in proteinuria
Group I Group II50% from previous values together with a normal se-
N20 N19 Prum albumin and normal renal function. Nephrotic syn-
Agea years 5316 5520 NSdrome was defined as a proteinuria3.5 g/24 h accompa-
r21–77 r24–81
nied by hypoalbuminemia (3 g/dL). Mean arterial Gender M/F 15/5 (75/25%) 11/8 (57/43%) NS
SCra mg/dL 1.41.0 1.40.7 NSpressure (MAP) was calculated as the diastolic blood
r0.7–5.3 r0.8–4pressure plus one third of the pulse pressure.
Proteinuriaa g/24 h 6.93.1 8.93.6 NS
r1–13.2 r4–15.6
Statistical analysis MAPa mm Hg 10312 10213 NS
r86–133 r86–133For statistical analysis, the paired and unpaired Stu-
Stage of MGN I 2 (10%) I 3 (15.7%) NS
dent t test and Mann-Whitney test were used where II 15 (75%) II 13 (68%)
III 3 (15%) III 3 (15.7%)appropriate. Fisher’s correction was applied when indi-
IV 0 IV 0cated. The study of data evolution throughout the study
Interval between renal biopsy 10.811.8 1418.6
period was performed by the analysis of variance for and the appearance of renal r0.1–49 r0.1–65
insufficiency monthsrepeated measurements (ANOVA). The cumulative
SCr mg/dL at the onset of 2.30.94probability of death or renal function survival without
immunosuppressive treatment r1.5–5.2
dialysis (censoring death without dialysis) was estimated Follow upb months 46.837.5 51.836.5 NS
r5–120 r8–120by the Kaplan-Meier method. The values are expressed
as mean  SD. P values 0.05 were considered statisti- a At the time of renal biopsy
b Follow-up defined as the interval between the appearance of renal insuffi-cally significant.
ciency and last visit, death or onset of chronic dialysis
RESULTS
During the first period (1975 to 1989), 67 patients were to 65 months). Except for four (20%) patients in group I
diagnosed at our Hospital of idiopathic MGN. Twenty and four (21%) in group II, renal function decline started
of them (29.8%; group I) showed renal insufficiency as within the first two years of evolution after renal biopsy.
described in the Methods section and were managed Proteinuria in the nephrotic range was observed in every
without immunosuppressive drugs. During the second patient of both groups coincidental with the onset of
period (1990 to 2000), 19 patients out of 55 cases of renal function derangement (8.6  3.4 g/24 h, r  3.8 to
idiopathic MGN diagnosed at our Hospital developed 14 in group I, and 11.2  3.3, r  7 to 21 in group II).
renal insufficiency (34.5%; group II). The main clinical Renal function decline continued progressing toward
and analytical features of both groups are shown in advanced renal failure in all the patients from group I,
Table 1. The interval between onset of the disease (ap- who received a conservative management (Fig. 1). After
pearance of edema, proteinuria detection) and the per- a mean follow up of 46.8  37.5 months (r  5 to 120
formance of renal biopsy was similar in both groups, months) SCr had increased from 2  0.8 mg/dL (r  1.5
ranging from 1 to 12 months. There were no significant to 5.3 mg/dL) to 6.7  2.8 (r  1.9 to 12.6 mg/dL; P 
differences in age, blood pressure, renal function or pro- 0.001; Fig. 2). Proteinuria in the nephrotic range was
teinuria at the time of renal biopsy. There was a majority observed in every patient during the progression of renal
of male patients in both groups (75% and 57%, without failure; however, when renal insufficiency was severe
significant differences). With the exception of five pa- there was a tendency to a decrease in proteinuria in
tients in group I and four in group II, all the patients relationship with advanced renal failure (Fig. 2). At the
had normal renal function (SCr 1.5 mg/dL and CCr end of the follow-up period (Table 2), 13 patients of this
60 mL/m) at the time of renal biopsy. Seventy-five group (65%) were on chronic dialysis, 2 (10%) showed
percent of group I patients and 78% of group II showed advanced renal failure and 5 (25%) had died, 2 because
nephrotic syndrome at renal biopsy. There were no dif- of sepsis, 1 with ischemic heart disease, 1 from stroke
ferences in the histological stage of MGN, as most of and, finally, 1 in unrecorded circumstances. All five pa-
the patients in both groups (75% and 68%, respectively) tients who died also showed a progressive renal insuffi-
showed stage II of the disease. The severity of interstitial ciency. No complete or partial remissions, as defined in
fibrosis was 1.2  0.3 (r  1 to 2) in group I and 1.3  the Methods sections, were observed in any patient of
0.4 (r  1 to 2) in group II. this group.
There were no significant differences in the time By contrast, renal function remained stable or im-
elapsed between renal biopsy and the appearance of proved in a majority of group II patients who received
renal insufficiency: 10.8 11.8 months in group I (range 0 a course of immunosuppressive treatment. Mean SCr at
the onset of treatment was 2.3  0.9 mg/dL (r  1.5 toto 49 months) and 14 18.6 months in group II (range 0
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Fig. 1. Evolution of serum creatinine (SCr) in
group I (conservative management; ) and
group II (immunosuppressive treatment; )
patients. Numbers in brackets represent the
number of patients at risk at every period.
Fig. 2. Serum creatinine (SCr) and proteinuria
values at the onset of renal function worsening
() and at the end of follow-up ( ) in treated
(group II) and non-treated (group I) patients.
5.2 mg/dL) and mean proteinuria 11.2  3.3 g/24 h (r  the onset of treatment). The mean follow-up of group II
patients was 51.8  36.5 months (r  8 to 120 months).7 to 21 g/24 h). Both SCr and proteinuria showed a rapid
and significant decrease after the introduction of predni- The mean SCr value at the end of follow-up was 2 
1.5 mg/dL (r  0.7 to 6.2 mg/dL), with no significantsone and chlorambucil treatment. After two months of
treatment SCr had decreased to 1.6  0.4 mg/dL (P  difference with respect to values at the onset of treat-
ment, whereas proteinuria remained significantly lower0.01) and at the completion (6 months) of treatment it
was 1.2 0.4 mg/dL (P 0.01). Proteinuria also showed (5.2  6.7 g/24 h, r  0 to 27 g/24 h; Fig. 2). At the end
of the follow-up (Table 2), five patients (26%) of thisa significant decrease by the fourth month of treatment
(6.8  5.2 g/24 h; P  0.05) and at the end of treatment group were in complete remission, two (10%) in par-
tial remission, and five (26%) showed a normal renalit was 5.6 3.5 g/24 h (P 0.01 with respect to values at
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Table 2. Clinical status at the end of follow-up later favorable evolution. Mean interval between renal
biopsy and the onset of renal derangement was almostGroup I Group II
N20 N19 twice as much among the eight treated patients with a
Non-treated Treated later evolution toward renal insufficiency (18.6  18 vs.
Complete remission 0 5 (26%) 10.7  19.1 months) and the proportion of males higher
Partial remission 0 2 (10.5%)
(6/2 vs. 5/6; Table 3), but these differences did not reachProteinuria 2.5 g/24 h
with normal statistical significance. There were significant differences
renal function 0 5 (26%) between group II patients with a favorable evolution
Chronic renal failure 2 (10%) 4 (21%)
and those with progression to renal insufficiency in theDialysis 13 (65%) 2 (10%)
Death 5 (25%) 2 (10%) slope of 1/SCr (0.0171  0.0214 vs. 0.0061  0.0049
dL/mg/month; P 0.05) and in the slope of CCr (1.2903
1.7230 vs. 0.6065  0.9092 mL/m/month; P  0.05).
A relapse of nephrotic-range proteinuria with renal
function deterioration was observed in two patients; bothfunction with proteinuria 2.5 g/24 h. Four patients
(21%) showed chronic renal insufficiency, two (10%) of them had achieved a partial remission with recovery
of a normal renal function after the first course of immu-were on chronic dialysis and two patients (10%) had
died, one of them because of a stroke despite a normal nosuppressive treatment. They were treated with a sec-
ond course of prednisone and chlorambucil at the samerenal function, and the other because of sepsis with a
SCr of 2.5 mg/dL. doses of the first course. One of the patients showed a
recovery of normal renal function (SCr 1.1 mg/dL at theThere were no significant differences in blood pressure
at the onset of renal function deterioration (MAP of last visit) with a reduction of proteinuria to a non-nephro-
tic range. The other patient did not show proteinuriagroup I 107  15 mm Hg, group II 100  10 mm Hg)
or during the first months of follow-up (after 6 months reduction with the treatment and his SCr is 2.5 mg/dL
of follow-up, the MAP of group I was 103  12 mm Hg one year after the end of the second course of immuno-
and that of group II, 98  12 mm Hg). Since the first suppressive treatment.
year of follow-up, group I showed a significantly higher The most important complications of immunosuppres-
blood pressure in relationship with the progression of sive treatment administered to group II patients are
renal failure in all the patients of this group. shown in Table 4. All these complications appeared after
As shown in Figure 3, the probability of renal survival the fourth month of treatment. The two cases of Pneumo-
without chronic dialysis (censoring death without chronic cystis carinii pneumonia showed a typical syndrome of
dialysis) was significantly higher in group II patients, severe dyspnea and extensive lung involvement on x-ray
who received immunosuppressive treatment: four years film of the thorax. The diagnosis was established by the
after the onset of renal function decline it was 90%, in demonstration of Pneumocystis on bronchopulmonary la-
comparison with a probability of 55% in group I, who vage. Both patients evolved satisfactorily with appropriate
was conservatively managed (P 0.01). After seven years treatment (trimethoprim-sulfametoxazole), although one
of follow-up these probabilities were 90% and 20%, re- of them needed assisted ventilation for two weeks.
spectively (P  0.01). Patient survival four years after
the onset of renal insufficiency was 84% in group II and
DISCUSSION78% in group I patients (P  NS). After seven years
Our study shows that immunosuppressive treatmentof follow-up, these probabilities were 84% and 63%,
(oral prednisone for 6 months plus oral chlorambucil ad-respectively (P  NS). At the end of the follow-up pe-
ministered concurrently for 31⁄2 months) of patients withriod, 11 patients (58%) of group II maintained a SCr
MGN and deteriorating renal function is a better thera-1.5 mg/dL, whereas all the patients of group I showed
peutic regimen than merely a conservative approach.a SCr 1.5 mg/dL. There were significant differences be-
Whereas all of the conservatively treated patients showedtween both groups in the slope of 1/SCr (group I0.0109
a progression of renal insufficiency, renal function im-0.0086 dL/mg/month; group II 0.0073  0.0201 dL/mg/
proved and proteinuria decreased in a considerable num-month, P 0.01) and the slope of CCr (group I1.1872
ber of patients treated with prednisone and chlorambu-1.5027 mL/m/month; group II 0.4916  1.7019 mL/m/
cil: at the end of follow up (51.8  36.5 months) moremonth, P  0.01).
than a half of the actively treated patients maintained aTable 3 shows that there were no significant differ-
serum creatinine lower than 1.5 mg/dL. The probabilityences between those patients of group II with a SCr
of renal survival without chronic dialysis was significantly1.5 mg/dL at the end of the follow-up (N  11) and
higher among patients who received immunosuppressivethe remaining 8 patients with SCr 1.5 mg/dL. Mean SCr
therapy (90% after 7 years of follow-up) in comparisonat the onset of immunosuppressive treatment was even
higher (2.7  1 vs. 1.8  0.3 mg/dL) in patients with a with patients treated with a conservative approach (20%
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Fig. 3. Probability of renal survival in group I
(no treatment; ) and group II (immunosup-
pressive treatment; ).
Table 4. Complications of immunosuppressive treatmentTable 3. Clinical features at the onset of immunosuppressive
treatment in group II patients with favorable (recovery of
Number of patientsnormal renal function) or unfavorable (renal insufficiency
at the end of follow-up) response to treatment Pneumocystis carinii pneumonia 2 (10.5%)
Herpes zoster 4 (21%)Normal renal function Renal insufficiency
Steroid psychoses 1 (5.2%)(SCr1.5 mg/dL) (SCr1.5 mg/dL) Steroid diabetes 1 (5.2%)N11 N8 P
Avascular bone necrosis 1 (5.2%)
Age years 5919 5021 NS
r26–81 r24–77
Gender M/F 5/6 6/2 NS
Interval between 10.719.1 18.618 NS
biopsy and onset of r0–65 r2–43 Previous studies have shown that approximately 50 to
immunosuppressive
60% of patients with idiopathic MGN never developtreatment months
SCr mg/dL 2.71 1.80.3 NS end-stage renal failure and almost a half of these may
r1.5–5.2 r1.6–2.5 have a spontaneous remission [6–11]. In one study 73%
Proteinuria g/24 h 11.13.1 11.34.1 NS
of untreated MGN patients retained adequate renalr7.2–15 r7.8–21
MAP mm Hg 10110 9811 NS function after eight years [2], and based on these results,
r86–116 r76–113 the authors did not recommend the use of steroids or
Stage of MGN 20.6 20.5 NS
immunosuppressive agents for this entity. However, ourr1–3 r1–3
Interstitial fibrosis 1.30.5 1.20.4 NS results show that in the subgroup of patients with a pro-
r1–2 r1–2 gressive renal insufficiency (31.9% in our experience) a
Follow-up months 4639 5932 NS
course of immunosuppressive therapy can avoid or delayr18–120 r8–117
the progression to end-stage renal failure, in comparison
with the uniform progression of untreated patients.
Another widely used therapeutic approach consists
in the administration of steroids and alkylating agentsafter 7 years of follow-up). Nephrotic-range proteinuria
(chlorambucil being the most commonly used) to pa-persisted in all the patients with a conservative manage-
tients with MGN and nephrotic syndrome before thement until they reached end-stage renal failure. Five
appearance of renal dysfunction. Studies from Ponticelli(25%) of them died during the follow-up. The high mor-
and collaborators have shown a long-term favorable in-tality and the causes of death illustrate well that a sus-
fluence of this therapy when compared to non-treatedtained nephrotic syndrome is a high-risk condition for
cardiovascular and infectious complications. patients [3–5]. The rationale for this early aggressive
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treatment (most patients with MGN present with ne- All of these reasons taken together (early evolution
phrotic syndrome) is that a persistent massive protein- of most patients toward spontaneous remission or pro-
uria would induce progressive tubulointerstitial damage, gressive renal derangement, high rate of spontaneous
even in those patients with a normal renal function main- remissions, and serious secondary effects of immunosup-
tained over several years. According to this hypothesis, pressive therapies), several groups have opted to reserve
when renal dysfunction appears, the presence of such aggressive treatment for patients who have early evi-
interstitial fibrosis would render any aggressive therapy dence of renal impairment. Several studies have reported
ineffective. However, several criticisms may be raised a beneficial influence of different immunosuppressive
against this approach: first, the appearance of renal insuf- strategies in patients with deteriorating renal function
ficiency is a relatively early event in MGN patients with [17–25]. However, comparison with the long-term out-
an unfavorable evolution; in our study, the mean interval come of untreated patients, as our study presents, had
between renal biopsy and appearance of renal dysfunc- not been performed yet.
tion was 10.8  11.8 months in the first period and 14  Alternating monthly cycles of steroids and chloram-
18.6 months in the second, ranging from 0 to 65 months. bucil for six months, based on the scheme of Ponticelli
Our findings corroborate that of previous studies [6], and collaborators [17, 22], oral cyclophosphamide and
showing that patients with a progressive course usually steroids for one to two years [18, 21], low-dose oral aza-
manifest decline of renal function within the first two thioprine plus steroids for very prolonged periods [23],
years of evolution. Most of spontaneous partial or com- and cyclosporine [27] have been reported to favorably
plete remissions also appear within the first two or three influence the course of idiopathic MGN with a progres-
years of initial diagnosis [6]. Therefore, only a few cases sive renal function decline. One exception for these gen-
maintain nephrotic-range proteinuria for more than two eral favorable results is the use of monthly intravenous
to three years without clinical evidence of spontaneous cyclophosphamide, which has been shown to be ineffec-
improvement or renal function decline. tive [20, 24]. We arbitrarily chose a modification of the
Another criticism against the early aggressive thera- Ponticelli protocol, using a concurrent, non-alternating
peutic approaches is that many patients who would spon- administration of oral steroids (progressively tapered for
taneously evolve into complete or partial remissions are 6 months) and oral chlorambucil (0.15 mg/kg/day for 14
included in immunosuppressive therapies. Although male weeks). This regimen is administered more easily than
sex and massive sustained proteinuria are associated with the alternating protocol that also includes intravenous
a poorer prognosis, only the appearance of a steady de- boluses of methylprednisolone [3–5].
cline of renal function could be considered as a constant Information about clinical characteristics at the onset
predictor of a poor outcome. Once renal function starts
of treatment that could influence the response to these
to decline, a progressive course toward end-stage renal
immunosuppressive regimens in MGN with deteriorat-disease ensues in almost all patients, as our untreated
ing renal function is scarce. When we compared thosepatients of group I exemplify.
cases of group II (who received prednisone plus chloram-On the other hand, immunosuppressive therapy is not
bucil) with a favorable response (11 out of 19 patients,without serious risks, as several previous studies have
58%) and the remaining 8 patients (42%) whose diseaseemphasized [19, 22, 23, 25, 26]. Our experience is in ac-
evolved into chronic renal failure, no significant differ-cordance with this general warning: although the total
ences were observed (Table 3). However, it should benumber of serious complications was relatively low, some
emphasized that the interval between renal biopsy andof them were particularly severe; two of our patients suf-
the onset of renal function decline was almost twice asfered a Pneumocystis carinii infection, which fortunately
much among the eight patients with an unfavorable evo-resolved with trimethoprim-sulphametoxazole treatment.
lution. Conceivably, a longer period of massive protein-We have not found previous reports of Pneumocystis
uria could induce a progressive tubulointerstitial fibrosiscarinii infection in patients with nephrotic syndrome,
[28] that, once renal function starts to decline, wouldalthough the number of respiratory infections as a com-
preclude a satisfactory long-term response to aggressiveplication of immunosuppressive therapies in MGN with
therapies. If this hypothesis is correct, immunosuppres-renal insufficiency was high in some studies [19, 20]. Our
sive therapy could be indicated in MGN patients withtwo cases illustrate how the combination of nephrotic
nephrotic syndrome lasting for more than 12 to 24 months,syndrome plus immunosuppressive therapy leads the pa-
even in the absence of a decline in renal function. An-tient to a severe immunodeficiency with the risk of very
other possible explanation could rely on the presencedangerous complications. Since the diagnosis of these
of reversible functional factors in the patients with atwo Pneumocystis pneumonia cases, we introduced into
favorable response. Nevertheless, factors such as over-our protocol a prophylaxis with trimethoprim-sulpha-
zealous diuretic therapy or acute impairments of renalmetoxazole for every actively treated MGN patient, and
no new cases of Pneumocystis infection have appeared. function induced by ACE inhibitors or NSAIDs were
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lone plus chlorambucil as compared with methylprednisolonecarefully ruled out in every patient before the onset of
alone for the treatment of idiopathic membranous glomerulopathy.
immunosuppressive treatment. N Engl J Med 327:599–603, 1992
5. Ponticelli C, Zucchelli P, Passerini IP, et al: A 10-year follow-upOur study has the limitations of a retrospective cohort
of a randomized study with methylprednisolone and chlorambucilstudy. Drugs such as ACE inhibitors and statins, that have
in membranous nephropathy. Kidney Int 48:1600–1604, 1995
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